Effects of topiramate and other anti-glutamatergic drugs on the acute intoxicating actions of ethanol in mice: Modulation by genetic strain and stress

Neuropsychopharmacology

Volumn 34, Issue 6, 2009, Pages 1454-1466

  Chen, Yi Chyan ^a   Holmes, Andrew ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol; Alcoholism; AMPA; Glutamate; NMDA; Treatment

Indexed keywords

ALCOHOL; DEXTROMETHORPHAN; DIZOCILPINE; HALOPERIDOL; LAMOTRIGINE; MEMANTINE; OXCARBAZEPINE; TOPIRAMATE;

ALCOHOL INTOXICATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CHRONIC STRESS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; FAMILY HISTORY; GENETIC STRAIN; HYPNOSIS; HYPOTHERMIA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SEDATION; STRAIN DIFFERENCE;

ALCOHOLIC INTOXICATION; ANIMALS; ATAXIA; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CONSCIOUS SEDATION; DEXTROMETHORPHAN; ETHANOL; EXCITATORY AMINO ACID AGENTS; FRUCTOSE; HALOPERIDOL; HYPOTHERMIA; MALE; MEMANTINE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; SPECIES SPECIFICITY; STRESS, PSYCHOLOGICAL; TRIAZINES;

EID: 64949160934     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.182     Document Type: Article

References (110)

1. Ahmad S, Fowler LJ, Whitton PS (2004a). Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 142: 136-142.
2. Ahmad S, Fowler LJ, Whitton PS (2004b). Effects of acute and chronic lamotrigine treatment on basal and stimulated extracellular amino acids in the hippocampus of freely moving rats. Brain Res 1029: 41-47.
3. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (2005). Memantine blocks alpha7 nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312: 1195-1205.
4. Backstrom P, Bachteler D, Koch S, Hyytia P, Spanagel R (2004). mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 29: 921-928.
5. Becker HC, Lopez MF (2004). Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. Alcohol Clin Exp Res 28: 1829-1838.
6. Beijamini V, Skalisz LL, Joca SR, Andreatini R (1998). The effect of oxcarbazepine on behavioural despair and learned helplessness. Eur J Pharmacol 347: 23-27.
7. Belzung C (2001). The genetic basis of the pharmacological effects of anxiolytics: a review based on rodent models. Behav Pharmacol 12: 451-460.
8. Bisaga A, Evans SM (2004). Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharma-cology (Berl) 172: 16-24.
9. Boyce-Rustay J, Palachick B, Hefner K, Karlsson RM, Millstein R, Harvey-White J et al. (2008a). Desipramine potentiation of the acute depressant effects of ethanol: modulation by alpha2-adrenoreceptors and stress. Neuropharmacology 55: 803-811.
10. Boyce-Rustay JM, Cameron HA, Holmes A (2007). Chronic swim stress alters sensitivity to acute behavioral effects of ethanol in mice. Physiol Behav 91: 77-86.
11. Boyce-Rustay JM, Cunningham CL (2004). The role of NMDA receptor binding sites in ethanol place conditioning. Behav Neurosci 118: 822-834.
12. Boyce-Rustay JM, Holmes A (2005). Functional roles of NMDA receptor NR2A and NR2B subunits in the acute intoxicating effects of ethanol in mice. Synapse 56: 222-225.
13. Boyce-Rustay JM, Holmes A (2006). Ethanol-related behaviors in mice lacking the NMDA receptor NR2A subunit. Psychopharmacology (Berl) 187: 455-466.
14. Boyce-Rustay JM, Janos AL, Holmes A (2008b). Effects of chronic swim stress on EtOH-related behaviors in C57BL/6J, DBA/2J and BALB/cByJ mice. Behav Brain Res 186: 133-137.
15. Broadbent J, Grahame NJ, Cunningham CL (1995). Haloperidol prevents ethanol-stimulated locomotor activity but fails to block sensitization. Psychopharmacology (Berl) 120: 475-482.
16. Brody SA, Geyer MA, Large CH (2003). Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 169: 240-246.
17. Cagetti E, Baicy KJ, Olsen RW (2004). Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats. Neuroreport 15: 207-210.
18. Carpenter-Hyland EP, Woodward JJ, Chandler LJ (2004). Chronic ethanol induces synaptic but not extrasynaptic targeting of NMDA receptors. J Neurosci 24: 7859-7868.
19. Cohen C, Perrault G, Sanger DJ (1997). Evidence for the involvement of dopamine receptors in ethanol-induced hyper-activity in mice. Neuropharmacology 36: 1099-1108.
20. Costa ET, Soto EE, Cardoso RA, Olivera DS, Valenzuela CF (2000). Acute effects of ethanol on Kainate receptors in cultured hippocampal neurons. Alcohol Clin Exp Res 24: 220-225.
21. Cowen MS, Djouma E, Lawrence AJ (2005). The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther 315: 590-600.
22. Cowen MS, Schroff KC, Gass P, Sprengel R, Spanagel R (2003). Neurobehavioral effects of alcohol in AMPA receptor subunit (GluR1) deficient mice. Neuropharmacology 45: 325-333.
23. Coyle JT (2006). Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res 10: 221-233.
24. Crabbe JC (2007). Overview of mouse assays of ethanol intoxication. Current Protocols in Neuroscience Wiley, Chapter 9: Unit 9.26.
25. Crabbe JC, Merrill CD, Belknap JK (1991). Effects of convulsants on handling-induced convulsions in mice selected for ethanol withdrawal severity. Brain Res 550: 1-6.
26. Crabbe JC, Metten P, Ponomarev I, Prescott CA, Wahlsten D (2006). Effects of genetic and procedural variation on measurement of alcohol sensitivity in mouse inbred strains. Behav Genet 36: 536-552.
27. Croissant B, Diehl A, Klein O, Zambrano S, Nakovics H, Heinz A et al. (2006). A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol Clin Exp Res 30: 630-635.
28. Cunningham CL, Malott DH, Dickinson SD, Risinger FO (1992). Haloperidol does not alter expression of ethanol-induced conditioned place preference. Behav Brain Res 50: 1-5.
29. Cunningham MO, Jones RS (2000). The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39: 2139-2146.
30. Daws LC, Montanez S, Munn JL, Owen AM, Baganz NL, Boyce-Rustay J et al. (2006). Ethanol inhibits clearance of brain serotonin by a serotonin transporter-independent mechanism. J Neurosci 26: 6431-6438.
31. Erden BF, Ozdemirci S, Yildiran G, Utkan T, Gacar N, Ulak G (1999). Dextromethorphan attenuates ethanol withdrawal syndrome in rats. Pharmacol Biochem Behav 62: 537-541.
32. Evans SM, Levin FR, Brooks DJ, Garawi F (2007). A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 31: 775-782.
33. Everitt BJ, Robbins TW (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8: 1481-1489.
34. Farook JM, Morrell DJ, Lewis B, Littleton JM, Barron S (2007). Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol 42: 296-300.
35. Files FJ, Denning CE, Samson HH (1998). Effects of the atypical antipsychotic remoxipride on alcohol self-administration. Pharmacol Biochem Behav 59: 281-285.
36. Fischer W, Franke H, Illes P (2003). Effects of acute ethanol on the Ca2+ response to AMPA in cultured rat cortical GABAergic nonpyramidal neurons. Alcohol Alcohol 38: 394-399.
37. Frye GD, Fincher A (2000). Sustained ethanol inhibition of native AMPA receptors on medial septum/diagonal band (MS/DB) neurons. Br J Pharmacol 129: 87-94.
38. Gabriel KI, Cunningham CL (2005). Effects of topiramate on ethanol and saccharin consumption and preferences in C57BL/6J mice. Alcohol Clin Exp Res 29: 75-80.
39. Gass JT, Olive MF (2008). Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 75: 218-265.
40. Goldman D, Oroszi G, Ducci F (2005). The genetics of addictions: uncovering the genes. Nat Rev Genet 6: 521-532.
41. Gordey M, DeLorey TM, Olsen RW (2000). Differential sensitivity of recombinant GABA(A) receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia 41(Suppl 1): S25-S29.
42. Grant BF, Goldstein RB, Chou SP, Huang B, Stinson FS, Dawson DA et al. (2008). Sociodemographic and psychopathologic predictors of first incidence of DSM-IV substance use, mood and anxiety disorders: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Mol Psychiatry, doi:10.1038/mp.2008.41
43. Gremel CM, Gabriel KI, Cunningham CL (2006). Topiramate does not affect the acquisition or expression of ethanol conditioned place preference in DBA/2J or C57BL/6J mice. Alcohol Clin Exp Res 30: 783-790.
44. Hargreaves GA, McGregor IS (2007). Topiramate moderately reduces the motivation to consume alcohol and has a marked antidepressant effect in rats. Alcohol Clin Exp Res 31: 1900-1907.
45. Hefner K, Holmes A (2007). An investigation of the behavioral actions of ethanol across adolescence in mice. Psychopharmacology (Berl) 191: 311-322.
46. Heilig M, Egli M (2006). Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111: 855-876.
47. Hodge CW, Miles MF, Sharko AC, Stevenson RA, Hillmann JR, Lepoutre V et al. (2006). The mGluR5 antagonist MPEP selectively inhibits the onset and maintenance of ethanol self-administration in C57BL/6J mice. Psychopharmacology (Berl) 183: 429-438.
48. Holter SM, Danysz W, Spanagel R (1996). Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol 314: R1-R2.
49. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004). Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 61: 905-912.
50. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K et al. (2003). Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361: 1677-1685.
51. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K et al. (2007). Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298: 1641-1651.
52. Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyurek M (2005). Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 19: 301-305.
53. Karlsson RM, Heilig M, Holmes A (2008). Loss of glutamate transporter GLAST (EAAT1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and mGlu2/3 agonist. Biol Psychiatry (in press).
54. Knapp CM, Mercado M, Markley TL, Crosby S, Ciraulo DA, Kornetsky C (2007a). Zonisamide decreases ethanol intake in rats and mice. Pharmacol Biochem Behav 87: 65-72.
55. Knapp DJ, Overstreet DH, Breese GR (2007b). Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res 31: 582-595.
56. Koethe D, Juelicher A, Nolden BM, Braunwarth WD, Klosterkotter J, Niklewski G et al. (2007). Oxcarbazepine-efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res 31: 1188-1194.
57. Komanduri R (2003). Two cases of alcohol craving curbed by topiramate. J Clin Psychiatry 64: 612.
58. Koob GF (2003). Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 27: 232-243.
59. Krupitsky EM, Neznanova O, Masalov D, Burakov AM, Didenko T, Romanova T et al. (2007a). Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am J Psychiatry 164: 519-523.
60. Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B et al. (2007b). Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res 31: 604-611.
61. Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC (2003). N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther 99: 79-94.
62. Kumari M, Ticku MK (2000). Regulation of NMDA receptors by ethanol. Prog Drug Res 54: 152-189.
63. Kuribara H (1994). Potentiation of the ambulation-increasing effect induced by combined administration of MK-801 with ethanol in mice. Psychopharmacology (Berl) 113: 453-456.
64. Lees G, Leach MJ (1993). Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex. Brain Res 612: 190-199.
65. Liu X, Weiss F (2002). Reversal of ethanol-seeking behavior by D1 and D2 antagonists in an animal model of relapse: differences in antagonist potency in previously ethanol-dependent versus nondependent rats. J Pharmacol Exp Ther 300: 882-889.
66. Lopez MF, Becker HC (2005). Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6J mice. Psychopharmacology (Berl) 181: 688-696.
67. Lovinger DM, White G, Weight FF (1989). Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science 243: 1721-1724.
68. Lynch DR, Gallagher MJ (1996). Inhibition of N-methyl-D-aspartate receptors by haloperidol: developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther 279: 154-161.
69. Meyer PJ, Phillips TJ (2003). Bivalent effects of MK-801 on ethanol-induced sensitization do not parallel its effects on ethanol-induced tolerance. Behav Neurosci 117: 641-649.
70. Millstein RA, Ralph RJ, Yang RJ, Holmes A (2006). Effects of repeated maternal separation on prepulse inhibition of startle across inbred mouse strains. Genes Brain Behav 5: 346-354.
71. Moykkynen T, Korpi ER, Lovinger DM (2003). Ethanol inhibits alpha-amino-3-hydyroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor function in central nervous system neurons by stabilizing desensitization. J Pharmacol Exp Ther 306: 546-555.
72. Mulholland PJ, Chandler LJ (2007). The thorny side of addiction: adaptive plasticity and dendritic spines. Scientific World Journal 7: 9-21.
73. Nankai M, Fage D, Carter C (1995). NMDA receptor subtype selectivity: eliprodil, polyamine spider toxins, dextromethorphan, and desipramine selectively block NMDA-evoked striatal acetylcholine but not spermidine release. J Neurochem 64: 2043-2048.
74. Newlin DB, Thomson JB (1990). Alcohol challenge with sons of alcoholics: a critical review and analysis. Psychol Bull 108: 383-402.
75. Nguyen SA, Malcolm R, Middaugh LD (2007). Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse 61: 150-156.
76. Norcross M, Mathur P, Enoch AJ, Karlsson RM, Brigman J, Cameron HA et al. (2008). Fluoxetine treatment during adolescence does not cause lasting deficits in fear-, anxiety-or stress-related behaviors in mice. Psychopharmacology (Berl) 200: 413-424.
77. Overstreet DH, Knapp DJ, Breese GR (2007). Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res 31: 1473-1481.
78. Palachick B, Chen Y-C, Enoch AJ, Karlsson RM, Mishina M, Holmes A (2008). Role of major NMDA or AMPA receptor subunits in MK-801 potentiation of ethanol intoxication. Alcohol Clin Exp Res 32: 1479-1492.
79. Parsons CG, Danysz W, Quack G (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38: 735-767.
80. Piasecki J, Koros E, Dyr W, Kostowski W, Danysz W, Bienkowski P (1998). Ethanol-reinforced behaviour in the rat: effects of uncompetitive NMDA receptor antagonist, memantine. Eur J Pharmacol 354: 135-143.
81. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG (2001). The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 306: 81-84.
82. Ramoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS et al. (1990). The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channels. J Pharmacol Exp Ther 254: 71-82.
83. Risinger FO, Dickinson SD, Cunningham CL (1992). Haloperidol reduces ethanol-induced motor activity stimulation but not conditioned place preference. Psychopharmacology (Berl) 107: 453-456.
84. Roberto M, Bajo M, Crawford E, Madamba SG, Siggins GR (2006). Chronic ethanol exposure and protracted abstinence alter NMDA receptors in central amygdala. Neuropsychopharmacol-ogy 31: 988-996.
85. Rubio G, Lopez-Munoz F, Alamo C (2006). Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord 8: 289-293.
86. Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F (2004). Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry 37: 37-40.
87. Rustay NR, Wahlsten D, Crabbe JC (2003). Influence of task parameters on rotarod performance and sensitivity to ethanol in mice. Behav Brain Res 141: 237-249.
88. Rustembegovic A, Sofic E, Kroyer G (2002). A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh 56: 211-212.
89. Sanchis-Segura C, Borchardt T, Vengeliene V, Zghoul T, Bachteler D, Gass P et al. (2006). Involvement of the AMPA receptor GluR-C subunit in alcohol-seeking behavior and relapse. J Neurosci 26: 1231-1238.
90. Schik G, Wedegaertner FR, Liersch J, Hoy L, Emrich HM, Schneider U (2005). Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal. Addict Biol 10: 283-288.
91. Schuckit MA (1994). Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry 151: 184-189.
92. High receptors. Synapse 62: 149-153.
93. Seeman P, Ko F, Tallerico T (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10: 877-883.
94. Shen EH, Phillips TJ (1998). MK-801 potentiates ethanol's effects on locomotor activity in mice. Pharmacol Biochem Behav 59: 135-143.
95. Sitges M, Chiu LM, Guarneros A, Nekrassov V (2007). Effects of carbamazepine, phenytoin, lamotrigine, oxcarbazepine, topiramate and vinpocetine on Na+ channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52: 598-605.
96. Smothers CT, Mrotek JJ, Lovinger DM (1997). Chronic ethanol exposure leads to a selective enhancement of N-methyl-D-aspartate receptor function in cultured hippocampal neurons. J Pharmacol Exp Ther 283: 1214-1222.
97. Snell LD, Yi SJ, Johnson KM (1988). Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol 145: 223-226.
98. Soyka M, Bondy B, Eisenburg B, Schutz CG (2000). NMDA receptor challenge with dextromethorphan - subjective response, neuroendocrinological findings and possible clinical implications. J Neural Transm 107: 701-714.
99. Spanagel R, Kiefer F (2008). Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29: 109-115.
100. Uzbay IT, Akarsu ES, Kayaalp SO (1994). Effects of bromocriptine and haloperidol on ethanol withdrawal syndrome in rats. Pharmacol Biochem Behav 49: 969-974.
101. Vanover KE (1999). Interaction of ethanol with excitatory amino acid receptor antagonists in mice. Eur J Pharmacol 368: 137-142.
102. Vengeliene V, Heidbreder CA, Spanagel R (2007). The effects of lamotrigine on alcohol seeking and relapse. Neuropharmacology 53: 951-957.
103. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M (1995). Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 45: 1907-1913.
104. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW (1996). Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7: 3037-3040.
105. Wang SJ, Sihra TS, Gean PW (2001). Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 12: 2255-2258.
106. White HS, Smith MD, Wilcox KS (2007). Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 81: 85-110.
107. Wiedholz LM, Owens WA, Horton RE, Feyder M, Karlsson RM, Hefner K et al. (2008). Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 13: 631-640.
108. Wilson WR, Bosy TZ, Ruth JA (1990). NMDA agonists and antagonists alter the hypnotic response to ethanol in LS and SS mice. Alcohol 7: 389-395.
109. Woodward JJ (2000). Ethanol and NMDA receptor signaling. Crit Rev Neurobiol 14: 69-89.
110. Zhao Y, Dayas CV, Aujla H, Baptista MA, Martin-Fardon R, Weiss F (2006). Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci 26: 9967-9974.